Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Total Debt (2019 - 2022)

BioScience Health Innovations has reported Total Debt over the past 4 years, most recently at $2893.0 for Q2 2022.

  • Quarterly Total Debt fell 82.47% to $2893.0 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $2893.0 through May 2022, down 82.47% year-over-year, with the annual reading at $17426.0 for FY2021, 123.1% up from the prior year.
  • Total Debt was $2893.0 for Q2 2022 at BioScience Health Innovations, down from $17426.0 in the prior quarter.
  • Over five years, Total Debt peaked at $17426.0 in Q3 2021 and troughed at $2893.0 in Q2 2022.
  • The 4-year median for Total Debt is $10956.5 (2020), against an average of $10899.3.
  • Year-over-year, Total Debt skyrocketed 157.8% in 2021 and then tumbled 82.47% in 2022.
  • A 4-year view of Total Debt shows it stood at $6115.0 in 2019, then skyrocketed by 130.61% to $14102.0 in 2020, then rose by 23.57% to $17426.0 in 2021, then crashed by 83.4% to $2893.0 in 2022.
  • Per Business Quant, the three most recent readings for BHIC's Total Debt are $2893.0 (Q2 2022), $17426.0 (Q4 2021), and $17426.0 (Q3 2021).